Oncology reportsPub Date : 2025-09-01Epub Date: 2025-07-04DOI: 10.3892/or.2025.8938
Wei Wang, Han Du, Huiping Liu, Fangfang Hu, Guangzhi Liu
{"title":"[Retracted] SMAD specific E3 ubiquitin protein ligase 1 promotes ovarian cancer cell migration and invasion via the activation of the RhoA/ROCK signaling pathway.","authors":"Wei Wang, Han Du, Huiping Liu, Fangfang Hu, Guangzhi Liu","doi":"10.3892/or.2025.8938","DOIUrl":"10.3892/or.2025.8938","url":null,"abstract":"<p><p>Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that a pair of the data panels shown for the Transwell migration assay experiments in Fig. 1B on p. 671, and two further pairs of data panels showing the results of invasion and migration assay experiments in Fig. 2A and B on p. 672 respectively, contained overlapping sections of data, such that the affected panels, which were intended to show the results of differently performed experiments, had all apparently been derived from the same original sources. Owing to the identification of these duplicated data panels in this paper, the Editor of <i>Oncology Reports</i> has decided that it should be retracted from the Journal on account of a lack of confidence in the presented data. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 41: 668‑676, 2019; DOI: 10.3892/or.2018.6836].</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology reportsPub Date : 2025-09-01Epub Date: 2025-06-20DOI: 10.3892/or.2025.8933
Tao Li, Chunfu Zhang, Yanling Ding, Wei Zhai, Kui Liu, Fan Bu, Tao Tu, Lingxian Sun, Wei Zhu, Fangfang Zhou, Wenkai Qi, Jiabo Hu, Huabiao Chen, Xiaochun Sun
{"title":"[Corrigendum] Umbilical cord‑derived mesenchymal stem cells promote proliferation and migration in MCF‑7 and MDA‑MB‑231 breast cancer cells through activation of the ERK pathway.","authors":"Tao Li, Chunfu Zhang, Yanling Ding, Wei Zhai, Kui Liu, Fan Bu, Tao Tu, Lingxian Sun, Wei Zhu, Fangfang Zhou, Wenkai Qi, Jiabo Hu, Huabiao Chen, Xiaochun Sun","doi":"10.3892/or.2025.8933","DOIUrl":"10.3892/or.2025.8933","url":null,"abstract":"<p><p>Subsequently to the publication of the above paper, an interested reader drew to the authors' attention that a pair of data panels appeared to contain overlapping data in each of Fig. 3A and C on p. 1473, showing the results of Transwell migration and scratch‑wound assay experiments respectively, where the data panels were intended to have shown the results from differently performed experiments; moreover, control GAPDH western blotting data featured in Fig. 4B and 5A appeared to be matching, albeit the bands had been inserted into these figure parts in reversed orientations. The authors were able to re‑examine their original data, and realized that errors had occurred in the assembly of these figures through mislabelling of certain of their data files. Owing to the time that had passed since this paper was published, the authors offered to repeat the affected experiments, and the revised versions of Figs. 3, 4 and 5, showing new data for Figs. 3A, 3C, 4B and 5A, are shown on the next two pages. Given that the new experiments yielded data that were not significantly different from those obtained previously, the authors wish to emphasize that the re‑presentation of these figures with the new data does not affect the overall conclusions reported in the paper. The authors are grateful to the Editor of <i>Oncology Reports</i> for allowing them the opportunity to publish this corrigendum, and all the authors agree with the publication of this corrigendum; moreover, they apologize to the readership for any inconvenience caused. [Oncology Reports 34: 1469‑1477, 2015; DOI: 10.3892/or.2015.4109].</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12218046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology reportsPub Date : 2025-09-01Epub Date: 2025-06-27DOI: 10.3892/or.2025.8934
Theodoros Rizopoulos, Martha Assimakopoulou
{"title":"Angiotensin‑converting enzyme 2 expression in human tumors: Implications for prognosis and therapy (Review).","authors":"Theodoros Rizopoulos, Martha Assimakopoulou","doi":"10.3892/or.2025.8934","DOIUrl":"10.3892/or.2025.8934","url":null,"abstract":"<p><p>Angiotensin‑converting enzyme 2 (ACE2) is one of the components of the renin‑angiotensin system. The differential expression of ACE2 is associated with carcinogenesis. ACE2 expression is altered in certain types of tumor following severe acute respiratory syndrome coronavirus 2 infection. The present review aimed to summarize the role of ACE2 expression in the pathogenesis of tumors of the central nervous and endocrine system, respiratory tract, breast, gastrointestinal tract, genitourinary system, skin and bone, as well as hematological malignancies. ACE2 should be further evaluated in the pathogenesis of various types of human tumor to determine its diagnostic and prognostic value. Additionally, the present review summarizes the potential of ACE2 as a novel therapeutic target for cancer. However, the role of ACE2 expression as a novel chemotherapeutic tool for various human malignancies remains to be fully elucidated.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144507317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology reportsPub Date : 2025-09-01Epub Date: 2025-06-27DOI: 10.3892/or.2025.8937
Feng Li, Qing Dong, Zhe Kai, Qi Pan, Chunsheng Liu
{"title":"CYP8B1 is a prognostic biomarker with important functional implications in hepatocellular carcinoma.","authors":"Feng Li, Qing Dong, Zhe Kai, Qi Pan, Chunsheng Liu","doi":"10.3892/or.2025.8937","DOIUrl":"10.3892/or.2025.8937","url":null,"abstract":"<p><p>Cytochrome P450 8B1 (CYP8B1) is a critical enzyme in bile acid metabolism. Using multiple databases, including Gene Expression Omnibus, UALCAN (The University of Alabama at Birmingham Cancer data analysis Portal, GEPIA (Gene Expression Profiling Interactive Analysis), TCGA (The Cancer Genome Atlas) and GTEx (Genotype‑Tissue Expression), the present study analyzed CYP8B1 expression and its prognostic value in hepatocellular carcinoma (HCC). The results showed that CYP8B1 expression was significantly lower in HCC compared with normal tissues, and reduced CYP8B1 expression was associated with poor prognosis in patients with HCC. CYP8B1 was overexpressed in HCC cell lines (Huh7 and Hep3b cells); cell proliferation was assessed using Cell Counting Kit‑8 and EdU assays, while apoptosis was evaluated using the TUNEL assay. CYP8B1 overexpression inhibited proliferation and promoted apoptosis in HCC cells. Additionally, analyses via UALCAN and the Metascape platform showed that CYP8B1 expression was negatively associated with YWHAZ (Tyrosine 3/tryptophan 5 monooxygenase activation protein ζ), the regulation of PLK (Polo‑like kinase) activity during G2/M transition, and the intrinsic apoptosis pathway. Immunoblotting revealed that CYP8B1 overexpression decreased YWHAZ levels. Consistently, the expression of cyclin‑dependent kinase 1) and CCNB1 (Cyclin B1), key markers of G2/M transition, was also diminished following CYP8B1 overexpression. Furthermore, the pro‑apoptotic protein Bax was upregulated, while the anti‑apoptotic protein Bcl‑2 was downregulated. In conclusion, CYP8B1 holds promise as a potential prognostic target for HCC.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144507318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology reportsPub Date : 2025-09-01Epub Date: 2025-07-04DOI: 10.3892/or.2025.8939
Vincenza Ciaramella, Barbara Carrese, Luigi Coppola, Giovanni Smaldone, Massimiliano D'Aiuto, Gennaro Mossetti, Andrea Soricelli, Marco Salvatore
{"title":"Evaluation of HMGB1 as possible marker via breast organoid cultures research.","authors":"Vincenza Ciaramella, Barbara Carrese, Luigi Coppola, Giovanni Smaldone, Massimiliano D'Aiuto, Gennaro Mossetti, Andrea Soricelli, Marco Salvatore","doi":"10.3892/or.2025.8939","DOIUrl":"https://doi.org/10.3892/or.2025.8939","url":null,"abstract":"<p><p>High mobility group box 1 (HMGB1) is a non‑histone protein widely expressed in the nucleus of mammalian cells, and it can be released by both immune and tumor cells. In the extracellular context HMGB1 can act as a proinflammatory mediator and boosting cancer progression. High HMGB1 mRNA expression levels are usually observed in various malignant diseases, including breast cancer (BC). Several studies have demonstrated the potential clinical value of HMGB1 in BC diagnosis and therapy. The present data, using <i>in vitro</i> protocols and molecular technologies, demonstrated the presence of HMGB1 in organoids derived from patients with BC with significantly elevated expression correlating with poorer prognosis. By blocking the activity of HMGB1 protein, cell cycle arrest and induction of apoptosis was observed in <i>ex vivo</i> 3D organoids, suggesting a potential antitumor effect. The localization by immunofluorescence, of HMGB1, β‑catenin and NF‑kB in organoids and the subsequent inhibition of the entire molecular pathway by switching off HMGB1 signaling suggests that there is a crosstalk between these molecules demonstrating their involvement in inflammation and inflammation‑associated diseases such as cancer. The current results aim to investigate the role of HMGB1 in BC progression and find innovative applications based on HMGB1 as a therapeutic target and early disease biomarker.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology reportsPub Date : 2025-09-01Epub Date: 2025-06-27DOI: 10.3892/or.2025.8936
Chao Zhang, Xiang Fan, Jia Yang, Pengfeng Zhu
{"title":"EIF3B‑METTL3 complex promotes cell proliferation, invasion and EGFR/AKT signaling in cervical cancer.","authors":"Chao Zhang, Xiang Fan, Jia Yang, Pengfeng Zhu","doi":"10.3892/or.2025.8936","DOIUrl":"10.3892/or.2025.8936","url":null,"abstract":"<p><p>Eukaryotic translation initiation factor 3B (EIF3B), a translation initiation factor, has been identified to directly interact with methyltransferase‑like (METTL) family members to regulate translation and oncogenic transformation in various types of cancers. However, the interaction mechanism of EIF3B with METTL3 has not yet been reported in cervical cancer (CC). The present study further investigated the interaction between EIF3B and METTL3, as well as their regulatory effect on the malignant behaviors of CC cells. EIF3B overexpression plasmid (oeEIF3B) or small interfering RNA (siRNA; siEIF3B) and negative controls (oeNC and siNC) were transfected into HeLa and SiHa cells. In addition, METTL3 siRNA (siMETTL3) and siNC were transfected along with oeEIF3B or oeNC into HeLa and SiHa cells. Co‑immunoprecipitation was performed to determine the interaction between EIF3B and METTL3. EIF3B expression was found to be elevated in CC cell lines (C‑33A, HeLa, SiHa and CaSki) compared with the control cell line. oeEIF3B accelerated the proliferation and invasion and attenuated the apoptosis of both HeLa and SiHa cells, while siEIF3B exerted an opposite effect. In addition, oeEIF3B activated the EGFR/AKT signaling pathway, whereas siEIF3B suppressed it. Of note, EIF3B and METTL3 formed a complex, according to co‑immunoprecipitation assay; moreover, EIF3B and METTL3 could not regulate the expression of each other. Regardless of the presence or absence of oeEIF3B, siMETTL3 suppressed cell proliferation and invasion, and inhibited EGFR/AKT signaling, while promoting the apoptosis of HeLa and SiHa cells. More importantly, oeEIF3B lost its effect on these cellular functions following the addition of siMETTL3, suggesting that the EIF3B‑METTL3 complex, but not EIF3B alone, plays a cancer‑promoting role in CC. On the whole, the present study demonstrates that the EIF3B‑METTL3 complex induces cell proliferation and invasion, and activates EGFR/AKT signaling in CC.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144507319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology reportsPub Date : 2025-09-01Epub Date: 2025-07-04DOI: 10.3892/or.2025.8940
Na Chen, Lili Feng, Huiting Qu, Kang Lu, Peipei Li, Xiao Lv, Xin Wang
{"title":"[Corrigendum] Overexpression of IL‑9 induced by STAT3 phosphorylation is mediated by miR‑155 and miR‑21 in chronic lymphocytic leukemia.","authors":"Na Chen, Lili Feng, Huiting Qu, Kang Lu, Peipei Li, Xiao Lv, Xin Wang","doi":"10.3892/or.2025.8940","DOIUrl":"https://doi.org/10.3892/or.2025.8940","url":null,"abstract":"<p><p>Following the publication of the above article, an interested reader drew to the authors' attention that, in Fig. 1A on p. 3067, the western blots shown for the STAT3 data in the upper right‑hand gels (for the N3, N4, and C5‑C8 experiments) were strikingly similar to the GAPDH data shown in the lower right‑hand gels (for the C14‑C16 and N6‑N8 experiments). Furthermore, in Fig. 2A on p. 3068, the phosphorylated (p‑)STAT western blots had apparently already appeared in a paper published by the same research group in the journal <i>International Journal of Clinical and Experimental Pathology</i>. After inspecting their original data, the authors realized that the data of interest in Figs. 1 and 2 had inadvertently been chosen incorrectly. The revised and corrected versions of Figs. 1 and 2, now showing replacement data for the upper and lower right‑hand gels in Fig. 1A and the upper three left‑hand panels in Fig. 2A, are shown on the next two pages. Note that the errors made with the assembly of the data in these figures did not affect the overall conclusions reported in the paper. The authors apologize to the Editor of <i>Oncology Reports</i> and to the readership for any inconvenience caused. [Oncology Reports 39: 3064‑3072, 2018; DOI: 10.3892/or.2018.6367].</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology reportsPub Date : 2025-09-01Epub Date: 2025-07-04DOI: 10.3892/or.2025.8941
Qibei Liu, Jianmin Ling, Zhao Li, Lintao Bi
{"title":"Advances in lymphoma biomarkers research based on proteomics technology (Review).","authors":"Qibei Liu, Jianmin Ling, Zhao Li, Lintao Bi","doi":"10.3892/or.2025.8941","DOIUrl":"10.3892/or.2025.8941","url":null,"abstract":"<p><p>Lymphoma is a common malignancy characterized by diverse pathological types and marked heterogeneity. Distinct subtypes of lymphomas are markedly different in their clinical manifestations, treatment approaches and prognostic outcomes. With the rapid development of molecular biology techniques, antitumor research has stepped into an era of precision medicine. Biomarkers, with high sensitivity and specificity, are expected to function in early diagnosis, targeted treatment and prognostic estimation for cancer and enhance the survival rate and life quality of patients. In this regard, proteomics technology, with the capability to systematically identify and quantify the dynamic protein alterations in tissues or cells, thereby facilitating the discovery of novel tumor potential candidates, has attracted significant scientific attention. The present article aimed to review most up‑to‑date research progress of lymphoma‑related biomarkers discovered based on proteomics technology, focusing on the potential application of these markers in the diagnosis, therapy and prognosis of each lymphoma subtype, and discuss the role proteomics may serve in future development of lymphoma research and clinical practice.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology reportsPub Date : 2025-09-01Epub Date: 2025-06-27DOI: 10.3892/or.2025.8935
Shiqi Wu, Jun Huang, Ke Hui, Yangyang Yue, Yanan Gu, Zhongyun Ning, Xinyang Wang, Dalin He, Kaijie Wu
{"title":"[Corrigendum] 2'‑Hydroxyflavanone inhibits epithelial‑mesenchymal transition, and cell migration and invasion via suppression of the Wnt/β‑catenin signaling pathway in prostate cancer.","authors":"Shiqi Wu, Jun Huang, Ke Hui, Yangyang Yue, Yanan Gu, Zhongyun Ning, Xinyang Wang, Dalin He, Kaijie Wu","doi":"10.3892/or.2025.8935","DOIUrl":"10.3892/or.2025.8935","url":null,"abstract":"<p><p>Following the publication of the above article, the authors contacted the Editorial Office to explain that they had made inadvertent errors in compiling the scratch‑wound assay images in Fig. 1B on p. 2838 and Fig. 4A on p. 2840; essentially, the same data had been included for the '2HF, 10 µM, 0 h' and '2HF, 5 µM, 12 h' experiments in Fig. 1B, and for the 'Vector, 2HF, 5 µM, 12 h' and '2HF, 5 µM, 24 h' experiments in Fig. 4A. However, the authors were able to re‑examine their original data, and realized how these errors had occurred. The revised and corrected versions of Figs. 1 and 4, now including replacement data for the experiments with the PC‑3 cell line (lower panel) in Fig. 1B and the Vector experiments with the DU145 cell line in Fig. 4A, are shown on the next two pages. Note that the errors made with the assembly of the data in these figures did not affect the overall conclusions reported in the paper. The authors apologize to the Editor of <i>Oncology Reports</i> and to the readership for any inconvenience caused. [Oncology Reports 40: 2836‑2843, 2018; DOI: 10.3892/or.2018.6678].</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 3","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144507316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology reportsPub Date : 2025-08-01Epub Date: 2025-06-20DOI: 10.3892/or.2025.8928
Kun Ma, Chuan Zhang, Man-Yu Huang, Wu-Yin Li, Guo-Qiang Hu
{"title":"[Retracted] Cinobufagin induces autophagy‑mediated cell death in human osteosarcoma U2OS cells through the ROS/JNK/p38 signaling pathway.","authors":"Kun Ma, Chuan Zhang, Man-Yu Huang, Wu-Yin Li, Guo-Qiang Hu","doi":"10.3892/or.2025.8928","DOIUrl":"10.3892/or.2025.8928","url":null,"abstract":"<p><p>Following the publication of this paper, it was drawn to the Editor's attention by a concerned reader that certain of the cellular data shown in Fig. 2C on p. 93 had already been submitted to another journal in an article written by different authors at different research institutes, which has subsequently been retracted. Moreover, upon performing an independent assessment of the data in the above paper in the Editorial Office, it emerged that flow cytometric data in Figs. 1 and 4 were also strikingly similar to data appearing in other unrelated articles, and western blot data appeared to have been shared between Fig. 6A and E on p. 97, where the results from differently performed experiments were intended to have been portrayed. Owing to the fact that the contentious data in the above article had already been submitted to/published in unrelated articles, and given the fact that Fig. 6 had clearly been assembled incorrectly, the Editor of <i>Oncology Reports</i> has decided that this paper should be retracted from the Journal. After having been in contact with the authors, they accepted the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 36: 90‑98, 2016; DOI: 10.3892/or.2016.4782].</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"54 2","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}